SCHEMBL4847192

SCHEMBL4847192

c1ccc(-c2cc(OCc3ccncc3)c3sccc3n2)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.44
ADORA1 P30542 2/20 0.44
IKBKB O14920 1/20 0.41
GPR39 O43194 1/20 0.39
PDE4A P27815 3/20 0.38
PDE4B Q07343 3/20 0.38
PDE4C Q08493 3/20 0.38
PDE4D Q08499 3/20 0.38
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
ABCB1 P08183 2/20 0.38
HRH4 Q9H3N8 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
METAP1 P53582 1/20 0.36
CCR1 P32246 1/20 0.35
CCR5 P51681 1/20 0.35
CCR8 P51685 1/20 0.35
SLC2A1 P11166 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6793662 0.87 IKBKB (0.50) IKBKBPDE4APDE4BPDE4CPDE4D
SCHEMBL4857946 0.84 MET (0.36) IKBKBPDE4APDE4BPDE4CPDE4D
SCHEMBL8140217 0.80 ADORA2A (0.50) ADORA2AADORA1NPSR1TDP1METAP1
SCHEMBL4854423 0.77 ADORA2A (0.42) ADORA2AADORA1METAP1SLC2A1
SCHEMBL6801328 0.74 IKBKB (0.54) ADORA2AIKBKBPDE4APDE4BPDE4C
SCHEMBL4854167 0.73 ATM (0.46) ADORA2AADORA1TDP1SLC2A1ATM
SCHEMBL4736973 0.72 CCR1 (0.51) ADORA2AADORA1TDP1METAP1CCR1
SCHEMBL4735939 0.72 ADORA2A (0.50) ADORA2AADORA1TDP1METAP1CCR1
SCHEMBL4855811 0.71 SYK (0.46)
SCHEMBL4854416 0.68 ADORA2A (0.39) ADORA2AADORA1METAP1SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050154008-A1 Aryl fused substituted 4-oxy-pyridines NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) 2005-07-14 US claimed
US-20020035121-A1 Aryl fused substituted 4-oxy-pyridines CAI GUOLIN (US) 2002-03-21 US claimed
US-7371752-B2 Aryl fused substituted 4-oxy-pyridines NEUROGEN CORPORATION (US) 2008-05-13 US disclosed
US-20050154008-A1 Aryl fused substituted 4-oxy-pyridines NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) 2005-07-14 US disclosed
US-6828329-B2 Agonists, antagonists for gamma-aminobutyric acid brain receptors useful in diagnosis and treatment of anxiety depressionm, down syndrome, sleep and seizure disorders NEUROGEN CORPORATION 2004-12-07 US disclosed
US-20020035121-A1 Aryl fused substituted 4-oxy-pyridines CAI GUOLIN (US) 2002-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154008-A1 Aryl fused substituted 4-oxy-pyridines CHRNA7, CHRNA4, GABRA6 ADORA2A 81/4885ADORA1 109/4885IKBKB 2129/4885
US-20020035121-A1 Aryl fused substituted 4-oxy-pyridines GABRA4, GABRA6, GABRG2 ADORA2A 73/4885ADORA1 80/4885IKBKB 1942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.